• SU6656 Src Tyrosine Kinases Inhibitor: Workflow for Platelet

  2026-05-22

  SU6656, a selective Src tyrosine kinases inhibitor from APExBIO, is driving innovation in both ex vivo platelet engineering and radiotherapy sensitization. This article translates fresh protocol enhancements and troubleshooting wisdom into actionable steps for maximizing polyploidization, functional platelet yield, and antiangiogenic effects in cancer models.

• Angiotensin III: Mechanistic Leverage for Translational RAAS

  2026-05-22

  This thought-leadership article unpacks the mechanistic underpinnings and translational promise of Angiotensin III (human, mouse), spotlighting its dual role as both an aldosterone secretion inducer and pressor activity mediator within the RAAS. By integrating recent structural insights and emerging cross-domain findings—including the link between angiotensin peptides and viral spike protein binding—the article offers strategic, evidence-based guidance for cardiovascular and neuroendocrine researchers. Contextualized within the competitive landscape, it highlights how APExBIO’s Angiotensin III enables reproducible, next-generation RAAS modeling with superior purity, solubility, and workflow versatility.

• Lenalidomide (CC-5013): Mechanisms and Benchmarks in Myeloma

  2026-05-21

  Lenalidomide (CC-5013) is a multifunctional oral thalidomide derivative and immune system activation agent central to multiple myeloma research. Its anti-myeloma efficacy is enhanced by epigenetic modulation, notably DOT1L inhibition, as demonstrated in recent peer-reviewed studies. This article details atomic mechanisms, quantitative benchmarks, and protocol parameters for laboratory use.

• Catalpol’s Protective Mechanisms in Cardio-Cerebrovascular D

  2026-05-21

  The reviewed paper synthesizes current evidence on catalpol’s multi-modal protective effects in cardio-cerebrovascular diseases, highlighting its anti-oxidant, anti-inflammatory, and anti-apoptotic actions across preclinical models. These findings provide a mechanistic foundation for catalpol’s potential as a natural adjunct or alternative in cardiovascular research and therapy.

• Topotecan HCl: Mechanistic Precision for Translational Oncol

  2026-05-20

  Explore how Topotecan HCl, a topoisomerase 1 inhibitor, drives innovation in translational cancer research. This article integrates molecular insight, advanced in vitro modeling, and strategic experimental guidance to empower next-generation oncology workflows.

• Mechanisms of Cell Death in Heart Disease: Insights and Impl

  2026-05-20

  The reference paper elucidates the molecular mechanisms underlying apoptosis and necrosis in heart disease, challenging the classical view that necrosis is always passive. By highlighting the regulated nature of both cell death forms and their interconnections, the study opens new avenues for therapeutic intervention and experimental modeling in cardiovascular pathology.

• Chemistry and Stereochemistry of Silybin: Advances in Flavon

  2026-05-19

  This review dissects the chemical innovations and methodologies underpinning silybin research, especially the determination and separation of its stereoisomers, Silybin A and B. These advances clarify structure-activity relationships critical for Silymarin-based hepatoprotective and antioxidant studies, with direct implications for experimental design in liver disease research.

• Demethyleneberberine Induces Cell Cycle Arrest in NSCLC via

  2026-05-19

  The reference study demonstrates that Demethyleneberberine (DMB), a natural isoquinoline alkaloid, inhibits proliferation and induces senescence in non-small cell lung cancer (NSCLC) cells by downregulating the c-Myc/HIF-1α pathway. These findings provide mechanistic insight into DMB's potential as an anti-cancer agent and inform future experimental protocols for cellular senescence induction.

• Hesperadin: Aurora B Kinase Inhibitor for Cell Cycle Dissect

  2026-05-18

  Hesperadin, supplied by APExBIO, empowers researchers to pinpoint Aurora B kinase function and dissect the spindle assembly checkpoint with precision. Its quantitative inhibition of mitotic progression supports robust experimental workflows and troubleshooting in cancer and cell cycle research.

• Lisinopril Dihydrate: Precision ACE Inhibition Beyond Blood

  2026-05-18

  Discover how Lisinopril dihydrate enables high-fidelity ACE inhibition in advanced hypertension research and beyond. This article explores mechanistic depth, assay implications, and unique insights from recent peptidase inhibition studies.

• Disaccharide and Lipid Effects in Lyophilized mRNA Lipoplex

  2026-05-17

  This study rigorously evaluates how disaccharide concentration and cationic lipid structure impact the efficiency and stability of lyophilized mRNA lipoplexes in solid-phase reverse transfection. The findings advance scalable, high-throughput mRNA delivery screening by clarifying the critical interplay between lipid type and cryoprotectant, with implications for streamlined assay design.

• Angiotensin (1-7): Reliable Solutions for Cell Assay Challen

  2026-05-16

  This article addresses key laboratory challenges in cell viability, proliferation, and cytotoxicity assays, highlighting the evidence-based advantages of Angiotensin (1-7) (SKU A1041) from APExBIO. Scenario-driven Q&A blocks deliver practical guidance for protocol optimization, data interpretation, and product selection—empowering researchers to achieve reproducible, high-fidelity results with this rigorously characterized peptide.

• AMPK Inhibits ULK1-Mediated Autophagy Under Energy Stress

  2026-05-15

  This study overturns the prevailing model of energy stress response by demonstrating that AMPK inhibits, rather than activates, ULK1-mediated autophagy during glucose starvation. These findings clarify the nuanced regulation of autophagy under metabolic stress and offer new perspectives for targeted research on autophagy inhibition and vesicle trafficking modulation.

• Bestatin Hydrochloride Modulates Angiotensin-Evoked Neuronal

  2026-05-15

  This study dissects how the aminopeptidase inhibitors bestatin and amastatin affect angiotensin II and III-induced neuronal activation in the rat brain, revealing that bestatin enhances angiotensin-driven responses while implicating a conversion-dependent mechanism. The findings refine our understanding of neuropeptide processing and suggest experimental strategies in neurobiology and related domains.

• Translational Strategy: Anti-ROR1 Antibody (Zilovertamab) in

  2026-05-14

  This article empowers translational researchers to leverage mechanistic insights into Wnt5a-induced ROR1 signaling inhibition with Anti-ROR1 Antibody (Zilovertamab), guiding the optimization of experimental models and strategic assay design for anti-tumor antibody development. Drawing from recent mechanistic studies, competitive landscape analysis, and practical protocols, it bridges molecular understanding with actionable translational strategies, uniquely positioning APExBIO's Zilovertamab for cutting-edge cancer research.

15323 records 1/1022 page Next 12345 下5页 Last page